JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Underwood, D. C.
Right arrow Articles by Torphy, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Underwood, D. C.
Right arrow Articles by Torphy, T. J.

Vol. 287, Issue 3, 988-995, December 1998

Antiasthmatic Activity of the Second-Generation Phosphodiesterase 4 (PDE4) Inhibitor SB 207499 (Ariflo) in the Guinea Pig

David C. Underwood, Steven Bochnowicz, Ruth R. Osborn, Charles J. Kotzer, Mark A. Luttmann, Douglas W.P. Hay, Peter D. Gorycki, Siegfried B. Christensen and Theodore J. Torphy

Departments of Pulmonary Pharmacology (D.C.U., S.B., R.R.O., C.J.K., M.A.L., D.W.P.H., T.J.T.), Drug Metabolism (P.D.G.) and Medicinal Chemistry (S.B.C.), SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania

We evaluated the airway activity of the novel phosphodiesterase type 4 inhibitor SB 207499 [Ariflo; c-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl-r-1-cyclohexane carboxylic acid)], in the guinea pig. Ovalbumin (OA)-induced contractions of guinea pig isolated tracheal strips were inhibited by SB 207499 with an EC50 of 1 µM but had little or no effect on exogenous agonist-induced contraction, which suggests that its effect on OA-induced contraction in vitro is primarily due to inhibition of mediator release from mast cells. In anesthetized guinea pigs, SB 207499 inhibited OA-induced bronchoconstriction with i.v. and p.o. ID50 values of 1.7 and 17 mg/kg, respectively. At 1, 3 and 6 hr after SB 207499 (30 mg/kg p.o.), OA-induced bronchospasm was inhibited by 92%, 70% and 58%, respectively, corresponding to elevated plasma concentrations of 1.62 ± 0.19, 1.65 ± 0.29 and 0.93 ± 0.24 µg/ml, respectively, of SB 207499. SB 207499 also inhibited house dust mite-induced bronchoconstriction (ID50 = 0.9 mg/kg i.v. and 8.9 mg/kg p.o.). In contrast to its lack of bronchorelaxant activity in vitro, SB 207499 inhibited bronchospasm induced by i.v. leukotriene D4 (LTD4) [ID50 = 3 mg/kg i.v.]. The bronchorelaxant effect of i.v.-administered SB 207499 was at least additive with that of salbutamol in reversing infused histamine-enhanced airway tone, but it did not alter base line or enhance salbutamol-induced cardiovascular effects. In conscious guinea pigs, SB 207499 (10 or 30 mg/kg p.o.), 1 hr before antigen or LTD4 challenge, markedly reduced bronchospasm and subsequent eosinophil influx as measured by bronchoalveolar lavage 24 hr after provocation. SB 207499 administered after OA or LTD4 challenge also reduced airway eosinophilia measured at 24 hr after OA challenge or 96 hr after LTD4 challenge. These results, coupled with the broad anti-inflammatory activity of SB 207499 previously described (), suggest that SB 207499 will be useful in the treatment of asthma and other inflammatory disorders.

0022-3565/98/2873-0988$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
V. Boswell-Smith, D. Spina, A. W. Oxford, M. B. Comer, E. A. Seeds, and C. P. Page
The Pharmacology of Two Novel Long-Acting Phosphodiesterase 3/4 Inhibitors, RPL554 [9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-Dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 840 - 848.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T.-L. Hwang, H.-W. Hung, S.-H. Kao, C.-M. Teng, C.-C. Wu, and S. J.-S. Cheng
Soluble Guanylyl Cyclase Activator YC-1 Inhibits Human Neutrophil Functions through a cGMP-Independent but cAMP-Dependent Pathway
Mol. Pharmacol., December 1, 2003; 64(6): 1419 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. M. Billah, N. Cooper, M. Minnicozzi, J. Warneck, P. Wang, J. A. Hey, W. Kreutner, C. A. Rizzo, S. R. Smith, S. Young, et al.
Pharmacology of N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline Carboxamide (SCH 351591), a Novel, Orally Active Phosphodiesterase 4 Inhibitor
J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 127 - 137.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. J. Haddad, S. C. Land, W. O. Tarnow-Mordi, M. Zembala, D. Kowalczyk, and R. Lauterbach
Immunopharmacological Potential of Selective Phosphodiesterase Inhibition. I. Differential Regulation of Lipopolysaccharide-Mediated Proinflammatory Cytokine (Interleukin-6 and Tumor Necrosis Factor-alpha ) Biosynthesis in Alveolar Epithelial Cells
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 559 - 566.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. S. Bundschuh, M. Eltze, J. Barsig, L. Wollin, A. Hatzelmann, and R. Beume
In Vivo Efficacy in Airway Disease Models of Roflumilast, a Novel Orally Active PDE4 Inhibitor
J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 280 - 290.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Aoki, M. Kobayashi, J. Ishikawa, Y. Saita, Y. Terai, K. Takayama, K. Miyata, and T. Yamada
A Novel Phosphodiesterase Type 4 Inhibitor, YM976 (4-(3-Chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with Little Emetogenic Activity
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 255 - 260.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. C. Underwood, R. R. Osborn, C. J. Kotzer, J. L. Adams, J. C. Lee, E. F. Webb, D. C. Carpenter, S. Bochnowicz, H. C. Thomas, D. W. P. Hay, et al.
SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence
J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 281 - 288.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.